LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary
care services, announces the launch by its Rex MD men’s health
brand of TestoRx, a new direct-to-consumer men’s hormone therapy
telehealth offering. TestoRx offers an initial consultation with
requisite blood tests to pre-screen patients, with treatment
options that include both replacement therapy and alternative
treatments to enhance endogenous hormone production – alongside
ongoing telehealth visits and follow-up care.
Rex MD is a leading men’s telehealth platform
that offers access to virtual medical treatment for a variety of
men’s health needs including erectile dysfunction, premature
ejaculation, hair loss and, most recently, weight management. The
addition of this new hormone replacement therapy program further
broadens Rex MD’s platform to better service its growing customer
base. Since its inception in 2019, Rex MD has served approximately
500,000 patients.
“We are pleased to introduce this new
testosterone therapy clinical offering as part of our Rex MD men’s
health services. TestoRx was designed in partnership with
clinicians renowned in their field to ensure a highly compliant
protocol with multiple treatment approaches focused on men with
clinically low testosterone,” said Justin Schreiber, Chairman and
Chief Executive Officer of LifeMD. “Our goal is to provide a
convenient and affordable solution to improve hormonal health for
men in the comfort of their own home.”
According to the Endocrine Society, male
hypogonadism (a condition in which the body produces little to no
testosterone) is common in the male population, with a higher
prevalence in older men, obese men and men with type 2 diabetes. It
is estimated that approximately 35% of men older than age 45 and
30-50% of men with obesity or type 2 diabetes have hypogonadism.
Furthermore, Rex MD de-identified data indicate that nearly 1 in 5
individuals self-report experiencing symptoms that can be signs of
conditions associated with low testosterone levels.
“As a leader in erectile dysfunction treatment
we know that, over time, men with hypogonadism can develop erectile
dysfunction, among other conditions. Additionally, obese men are
more likely to have low testosterone levels, with an expansion in
waist size notably increasing the odds of conditions associated
with low testosterone – an audience we are increasingly engaging
with as part of our weight management program. Accordingly, TestoRx
is a clinically important and sought after component of building
our comprehensive men’s health offering,” added Anthony Puopolo,
M.D., President, LifeMD Affiliated P.C.s.
About LifeMD
LifeMD is a leading provider of virtual primary
care. LifeMD offers telemedicine, access to laboratory and pharmacy
services, and specialized treatment across more than 200
conditions, including primary care, men’s and women's health,
weight management, and hormone therapy. The Company leverages a
vertically-integrated, proprietary digital care platform, a
50-state affiliated medical group, and a U.S.-based patient care
center to increase access to high-quality and affordable care. For
more information, please visit LifeMD.com.
Cautionary Note Regarding Forward
Looking Statements
This news release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended; Section 21E of the Securities Exchange Act of
1934, as amended; and the safe harbor provision of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this news release may be identified by the
use of words such as: “believe,” “expect,” “anticipate,” “project,”
“should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,”
“continue,” and “potential,” or, in each case, their negative or
other variations or comparable terminology referencing future
periods. Examples of forward-looking statements include, but are
not limited to, statements regarding our financial outlook and
guidance, short and long-term business performance and operations,
future revenues and earnings, regulatory developments, legal events
or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products
and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations
or financial condition.
Forward-looking statements are not historical
facts and are not assurances of future performance. Rather, these
statements are based on our current expectations, beliefs, and
assumptions regarding future plans and strategies, projections,
anticipated and unanticipated events and trends, the economy, and
other future conditions, including the impact of any of the
aforementioned on our future business. As forward-looking
statements relate to the future, they are subject to inherent risk,
uncertainties, and changes in circumstances and assumptions that
are difficult to predict, including some of which are out of our
control. Consequently, our actual results, performance, and
financial condition may differ materially from those indicated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, “Risk Factors” identified in our
filings with the Securities and Exchange Commission, including, but
not limited to, our most recently filed Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and any amendments thereto. Even if
our actual results, performance, or financial condition are
consistent with forward-looking statements contained in such
filings, they may not be indicative of our actual results,
performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news
release is based on information currently available to us as of the
date on which this release is made. We undertake no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as may be
required under applicable law or regulation.
Investor ContactMarc Benathen,
Chief Financial Officermarc@lifemd.com
Media Contact Jessica
Friedeman, Chief Marketing Officerpress@lifemd.com
LifeMD (NASDAQ:LFMDP)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
LifeMD (NASDAQ:LFMDP)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024